Clinical trials: Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from…
- Trial name
- STRATHEP (NCT07863258)
- Where
- 5 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
This phase II trial is studying how well giving cediranib maleate together with combination chemotherapy works in treating patients with advanced biliary cancers.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01229111
- Testing
- cediranib maleate, oxaliplatin, leucovorin calcium
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better.
- Trial name
- RADIANT (NCT07312292)
- Testing
- Angiotensin II (Giapreza®), Yttrium-90 radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Niek Wijnen
Advanced Hepatocellular Carcinoma (HCC)
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects…
- Trial name
- NCT04212221
- Testing
- MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Hepatocellular Carcinoma
ABT-888 and Temozolomide for Liver Cancer
This study is for people with liver cancer (also called hepatocellular carcinoma, or HCC in abbreviation). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and temozolomide…
- Trial name
- NCT01205828
- Testing
- Temozolomide, ABT-888
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Georgetown University
Hepatocellular Carcinoma Non-resectable
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05608200
- Testing
- Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19…
- Trial name
- NCT07327034
- Testing
- ABSK-011+BSC
- Where
- 51 sites in China
- Volunteers
- 141 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage…
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06632106
- Testing
- hepatic artery infusion chemotherapy, Tyrosine kinase inhibitor (TKIs), Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Hospital of China Medical University
Advanced Hepatocellular Carcinoma
Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study
To investigate the efficacy and safety of sorafenib administered as later lines of treatment in patients with advanced HCC.
- Trial name
- NCT05117957
- Testing
- Sorafenib
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Bo Hyun Kim
Hepatocellular Carcinoma
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- LIVIGNO-1 (NCT05822752)
- Testing
- Budigalimab, Livmoniplimab, Lenvatinib
- Where
- 59 sites in United States, France and 5 more
- Volunteers
- 130 people
- Sponsor
- AbbVie
Advanced Solid Tumors, NSCLC
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have…
- Conditions
- Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC
- Trial name
- NCT04157985
- Testing
- Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Dan Zandberg
Carcinoma, Hepatocellular
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative…
- Trial name
- NCT00582400
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Carcinoma, Hepatocellular
Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase
Primary Outcome Measures: To compare the progression free survival(PFS) in patients with unresectable hepatocellular carcinoma(HCC) treated with transcatheter arterial chemoembolization(TACE) with or without Huachansu, and the…
- Trial name
- NCT01715532
- Testing
- Huachansu, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Hepatocellular Cancer
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.
- Trial name
- NCT06935175
- Testing
- SHR-1826, SHR-1826 and immunotherapy combination therapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Shanghai Zhongshan Hospital
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Progress Free Survival (PFS) and Overall Survival (OS)
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
- Trial name
- NCT04393220
- Testing
- Bevacizumab Injection, Nivolumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04592029
- Testing
- TACE combined with sintilimab and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Fibrolamellar Hepatocellular Carcinoma
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective…
- Trial name
- NCT06027086
- Testing
- Durvalumab, DRP-104
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.